FBFrancesco Barchiesi

Francesco Barchiesi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francesco Barchiesi has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Elisabetta Spreghini

    Istituto di Malattie Infettive e Medicina Pubblica,1 Centro di Gestione Presidenza Medicina e Chirurgia, Università Politecnica delle Marche, Ancona, Italy2

    9 shared publications
  • Giorgio Scalise

    Istituto di Malattie Infettive e Medicina Pubblica,1 Centro di Gestione Presidenza Medicina e Chirurgia, Università Politecnica delle Marche, Ancona, Italy2

    9 shared publications
  • Daniele Giannini

    Istituto di Malattie Infettive e Medicina Pubblica,1 Centro di Gestione Presidenza Medicina e Chirurgia, Università Politecnica delle Marche, Ancona, Italy2

    8 shared publications
  • Daniela Arzeni

    Istituto di Malattie Infettive e Medicina Pubblica, Università Politecnica delle Marche,1 Laboratorio di Microbiologia, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I°-Lancisi-Salesi, Ancona, Italy2

    4 shared publications
  • Annette W. Fothergill

    Istituto di Malattie Infettive e Medicina Pubblica,1 Istituto di Anatomia Patologica,2 Centro Gestione Presidenza Medicina e Chirurgia, Università Politecnica delle Marche, Ancona, Italy,3 Department of Pathology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas,4 Audie L. Murphy Division, South Texas Veterans Health Care System, San Antonio, Texas5

    3 shared publications
  • Michael G. Rinaldi

    Istituto di Malattie Infettive e Medicina Pubblica,1 Istituto di Anatomia Patologica,2 Centro Gestione Presidenza Medicina e Chirurgia, Università Politecnica delle Marche, Ancona, Italy,3 Department of Pathology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas,4 Audie L. Murphy Division, South Texas Veterans Health Care System, San Antonio, Texas5

    3 shared publications

Latest Publications

  • Caspofungin in Combination with Amphotericin B against Candida parapsilosis

    by Francesco Barchiesi, Elisabetta Spreghini, Serena Tomassetti, Daniele Giannini, Giorgio Scalise

    C andida parapsilosis has emerged as an important nosocomial pathogen. In the present study, a checkerboard broth microdilution method was performed to investigate the in vitro activities of caspofungin (CAS) in combination with amphotericin B (AMB) against three clinical isolates of C. parapsilosis . Although there was a significant reduction of the MIC of one or both drugs used in combination, an indifferent interaction (fractional inhibitory concentration index greater than 0.50 and less than or equal to 4.0) was observed in 100% of cases. This finding was confirmed by killing curve studies. By a disk diffusion assay, the halo diameters produced by antifungal agents in combination were often significantly greater than those produced by each drug alone. Antagonism was never observed. In a murine model of systemic candidiasis, CAS at either 0.25 or 1 mg/kg/day combined with AMB at 1 mg/kg/day was significantly more effective than each single drug at reducing the colony counts in kidneys. Higher doses of the echinocandin (i.e., 5 and 10 mg/kg/day) combined with the polyene did not show any advantage over CAS alone. Overall, our study showed a positive interaction of CAS and AMB against C. parapsilosis .


  • Fluconazole Susceptibility ofCandidaspp. Isolates Collected Over Nine Years in a Teaching Hospital of Ancona, Italy

    by F. Barchiesi, D. Arzeni, G. Greganti, A. Marigliano, S. Tomassetti, E. Spreghini, G. Scalise

    The in vitro activity of fluconazole was investigated against 476 yeast isolates collected during a 9-year period (1997-2005) from patients hospitalised in a teaching hospital of Ancona. They included 373 isolates of Candida albicans, 53 of Candida glabrata and 50 of Candida parapsilosis. Minimum inhibitory concentrations (MICs) determined in accordance with the Clinical Laboratory Standards Institute methodology showed that 96% of the isolates were susceptible (MIC < or =8.0 microg/ml). The uncommon, resistant isolates (MIC > or =64 microg/ml) were randomly distributed over time. Our data show that resistance to fluconazole in this geographical area is a rare event and suggest that this triazole can still represent first-line therapy in our institution.


  • Posaconazole Prophylaxis in Experimental Systemic Zygomycosis

    by Francesco Barchiesi, Elisabetta Spreghini, Alfredo Santinelli, Annette W. Fothergill, Eleonora Pisa, Daniele Giannini, Michael G. Rinaldi, Giorgio Scalise

    Three isolates of zygomycetes belonging to two different genera (Rhizopus oryzae and Absidia corymbifera) were used to produce a systemic infection in neutropenic mice. On days -2 and -1 and at 2 h prior to infection, the mice received either posaconazole (POS) at doses ranging from 20 to 80 mg/kg of body weight/day or amphotericin B (AMB) at 1 mg/kg/day. Antifungal drug efficacy was assessed by determination of the prolongation of survival, determination of the percentage of infected organs (brain, lung, spleen, and kidney), and histological examination for the number of infection foci and their sizes in brain and kidney tissues. AMB significantly prolonged the survival of mice infected with all isolates. POS significantly prolonged the survival of mice infected with zygomycetes. Cultured organs from mice infected with R. oryzae were all positive, while treated mice challenged with A. corymbifera generally showed lower percentages of infected organs compared with the percentages for the controls. Zygomycete isolates established an active infection (the presence of hyphae) in the brains and the kidneys of all controls. In mice challenged with R. oryzae, both antifungal drugs were effective at reducing the number and the size of infection foci in the kidneys. Only AMB reduced the numbers, but not the sizes, of infection foci in the brain. Finally, both drugs significantly reduced the numbers and the sizes of infection foci in both tissues of mice infected with A. corymbifera. Our data suggest that prophylaxis with POS has some potential to prevent zygomycosis.


  • Effects of Caspofungin against Candida guilliermondii and Candida parapsilosis

    by Francesco Barchiesi, Elisabetta Spreghini, Serena Tomassetti, Agnese Della Vittoria, Daniela Arzeni, Esther Manso, Giorgio Scalise

    The in vitro activity of caspofungin (CAS) was investigated against 28 yeast isolates belonging to Candida albicans ( n = 5), Candida guilliermondii ( n = 10), and Candida parapsilosis ( n = 13). CAS MICs obtained by broth dilution and Etest methods clearly showed a rank order of susceptibility to the echinocandin compound with C. albicans > C. parapsilosis > C. guilliermondii . Similarly, time-kill assays performed on selected isolates showed that CAS was fungistatic against C. albicans and C. parapsilosis , while it did not exert any activity against C. guilliermondii . In a murine model of systemic candidiasis, CAS given at doses as low as 1 mg/kg of body weight/day was effective at reducing the kidney burden of mice infected with either C. albicans or C. guilliermondii isolates. Depending on the isolate tested, mice infected with C. parapsilosis responded to CAS given at 1 and/or 5 mg/kg/day. However, the overall CFU reduction for C. guilliermondii and C. parapsilosis was approximately 100-fold less than that for C. albicans . Our study shows that CAS was active in experimental systemic candidiasis due to C. guilliermondii and C. parapsilosis , but this activity required relatively high drug dosages.


  • Open Access

    Comparison of the Fungicidal Activities of Caspofungin and Amphotericin B against Candida glabrata

    by Francesco Barchiesi, Elisabetta Spreghini, Serena Tomassetti, Daniela Arzeni, Daniele Giannini, Giorgio Scalise

    We investigated the fungicidal activity of caspofungin (CAS) and amphotericin B (AMB) against 16 clinical isolates of Candida glabrata. The minimum fungicidal concentrations (MFCs) of CAS were similar to those of AMB, ranging from 2.0 to >8.0 μg/ml. Time-kill assays performed on selected isolates showed that AMB was fungicidal at concentrations four times the MIC while CAS was not. A neutropenic-mouse model of disseminated infection was utilized to determine the residual fungal kidney burden. While doses as low as 0.3 and 1 mg/kg of body weight/day of CAS and AMB, respectively, were effective at reducing the counts with respect to controls, organ sterilization was reached when both drugs were administered at 5 mg/kg/day. Our study reveals that, similar to AMB, CAS has the potential for a fungicidal effect in vivo against this difficult-to-treat fungal pathogen.


  • Open Access

    Efficacy of Caspofungin against Aspergillus terreus

    by Francesco Barchiesi, Elisabetta Spreghini, Alfredo Santinelli, Annette W. Fothergill, Stefania Fallani, Esther Manso, Eleonora Pisa, Daniele Giannini, Andrea Novelli, Maria I. Cassetta, et al.

    We investigated the in vitro and in vivo activities of caspofungin against Aspergillus terreus . The drug increased survival and reduced tissue fungal burden in neutropenic mice. Therefore, our data support the role of caspofungin in treating systemic infections due to this emerging pathogen.


  • Comparative analysis of pathogenicity of Cryptococcus neoformans serotypes A, D and AD in murine cryptococcosis

    by F. Barchiesi, M. Cogliati, M.C. Esposto, E. Spreghini, A.M. Schimizzi, B.L. Wickes, G. Scalise, M.A. Viviani


  • Caspofungin in Combination with Amphotericin B against Candida glabrata

    by Francesco Barchiesi, Elisabetta Spreghini, Annette W. Fothergill, Daniela Arzeni, Gianfranco Greganti, Daniele Giannini, Michael G. Rinaldi, Giorgio Scalise

    The effects of caspofungin combined with amphotericin B were investigated with Candida glabrata . Although in vitro experiments showed an indifferent interaction, the combination regimen was the only therapeutic approach yielding organ sterilization in a murine candidemia model.


  • Open Access

    Genotypic variation and antifungal susceptibilities of Candida pelliculosa clinical isolates

    by F Barchiesi, A M Tortorano, L Falconi Di Francesco, A Rigoni, A Giacometti, E Spreghini, G Scalise, M A Viviani

    At the Istituto Ricovero Cura Carattere Scientifico, Ospedale Maggiore di Milano, Italy,Candida pelliculosaaccounted for 3.3 and 4.4 % of allCandidaspecies other thanCandida albicanscollected during 1996 and 1998, respectively. Genetic variability was investigated by electrophoretic karyotyping and inter-repeat PCR, and the susceptibility to five antifungal agents of 46 strains isolated from 37 patients during these 2 years was determined. Combination of the two typing methods yielded 14 different DNA types. Although the majority of DNA types were randomly distributed among different units, one DNA type was significantly more common in patients hospitalized in a given unit compared with those from other wards (P= 0.034), whereas another DNA type was more frequently isolated in patients hospitalized during 1996 than in those hospitalized during 1998 (P= 0.002). Fluconazole, itraconazole and posaconazole MIC90values were 16, 1 and 4 μg ml−1, respectively. All isolates but three were susceptiblein vitroto flucytosine. All isolates were susceptiblein vitroto amphotericin B. These data suggest that there are possible relationships among strains ofC. pelliculosa, wards and time of isolation. Amphotericin B seems to be the optimal drug therapy in infections due to this yeast species.


  • Tolerance to amphotericin B in clinical isolates of Candida tropicalis

    by Francesco Barchiesi, Monia Maracci, Isabella Baldassarri, Elisabetta Spreghini, Daniele Giannini, Giorgio Scalise